In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wilson Therapeutics AB

https://www.wilsontherapeutics.com/en

Latest From Wilson Therapeutics AB

BioAge Puts VC Muscle Behind Phase II Azelaprag Trials In Obesity

The company completed a $170m series D round and plans to start trials combining the drug with GLP-1 agonists like Eli Lilly’s Zepbound in mid-2024.

Financing StartUps and SMEs

Zydus MD On Pipeline-In-A-Drug Approach, Partnering Intent

Zydus MD Sharvil Patel talks to Scrip about a pipeline-in-a-drug approach for novel molecules like ZYIL-1, the intent behind deals with Daewoong and LiqMeds and expected timelines for trial readouts of its PBC/NASH candidate saroglitazar

Commercial Clinical Trials

Veru Hopes To Position Enobosarm As Muscle-Protective In Weight-Loss Therapy

A selective androgen receptor modulator also being studied in metastatic breast cancer, enobosarm might offer potential as add-on therapy to GLP-1 agonists prescribed for weight loss, the Miami biotech asserts.

Clinical Trials Drug Approval Standards

BioAge Looks To Tackle Diseases Of Aging, Starting With Muscle Loss

Emerging Company Profile: BioAge has Phase Ib proof-of-concept data in age-related muscle loss and is gearing up for its first Phase II study, but will need fresh cash or a partner for a potential weight loss-related muscle loss study.

Companies Clinical Trials
See All

Company Information

UsernamePublicRestriction

Register